245 related articles for article (PubMed ID: 32541028)
1. Structure-guided engineering of the affinity and specificity of CARs against Tn-glycopeptides.
Sharma P; Marada VVVR; Cai Q; Kizerwetter M; He Y; Wolf SP; Schreiber K; Clausen H; Schreiber H; Kranz DM
Proc Natl Acad Sci U S A; 2020 Jun; 117(26):15148-15159. PubMed ID: 32541028
[TBL] [Abstract][Full Text] [Related]
2. Single CAR-T cell treatment controls disseminated ovarian cancer in a syngeneic mouse model.
Ranoa DRE; Sharma P; Schane CP; Lewis AN; Valdez E; Marada VVVR; Hager MV; Montgomery W; Wolf SP; Schreiber K; Schreiber H; Bailey K; Fan TM; Hergenrother PJ; Roy EJ; Kranz DM
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37258040
[TBL] [Abstract][Full Text] [Related]
3. Characterization of an immunodominant cancer-specific O-glycopeptide epitope in murine podoplanin (OTS8).
Steentoft C; Schjoldager KT; Cló E; Mandel U; Levery SB; Pedersen JW; Jensen K; Blixt O; Clausen H
Glycoconj J; 2010 Aug; 27(6):571-82. PubMed ID: 20721622
[TBL] [Abstract][Full Text] [Related]
4. Bispecific chimeric antigen receptors targeting the CD4 binding site and high-mannose Glycans of gp120 optimized for anti-human immunodeficiency virus potency and breadth with minimal immunogenicity.
Ghanem MH; Bolivar-Wagers S; Dey B; Hajduczki A; Vargas-Inchaustegui DA; Danielson DT; Bundoc V; Liu L; Berger EA
Cytotherapy; 2018 Mar; 20(3):407-419. PubMed ID: 29306566
[TBL] [Abstract][Full Text] [Related]
5. T-cell recognition of tumor-associated carbohydrates: the nature of the glycan moiety plays a decisive role in determining glycopeptide immunogenicity.
Galli-Stampino L; Meinjohanns E; Frische K; Meldal M; Jensen T; Werdelin O; Mouritsen S
Cancer Res; 1997 Aug; 57(15):3214-22. PubMed ID: 9242452
[TBL] [Abstract][Full Text] [Related]
6. Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma.
Posey AD; Schwab RD; Boesteanu AC; Steentoft C; Mandel U; Engels B; Stone JD; Madsen TD; Schreiber K; Haines KM; Cogdill AP; Chen TJ; Song D; Scholler J; Kranz DM; Feldman MD; Young R; Keith B; Schreiber H; Clausen H; Johnson LA; June CH
Immunity; 2016 Jun; 44(6):1444-54. PubMed ID: 27332733
[TBL] [Abstract][Full Text] [Related]
7. Tumor-associated MUC1 glycopeptide epitopes are not subject to self-tolerance and improve responses to MUC1 peptide epitopes in MUC1 transgenic mice.
Ryan SO; Vlad AM; Islam K; Gariépy J; Finn OJ
Biol Chem; 2009 Jul; 390(7):611-8. PubMed ID: 19426130
[TBL] [Abstract][Full Text] [Related]
8. Impact of scFv structure in chimeric antigen receptor on receptor expression efficiency and antigen recognition properties.
Fujiwara K; Masutani M; Tachibana M; Okada N
Biochem Biophys Res Commun; 2020 Jun; 527(2):350-357. PubMed ID: 32216966
[TBL] [Abstract][Full Text] [Related]
9. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
[TBL] [Abstract][Full Text] [Related]
10. Analysis of Tn antigenicity with a panel of new IgM and IgG1 monoclonal antibodies raised against leukemic cells.
Blixt O; Lavrova OI; Mazurov DV; Cló E; Kracun SK; Bovin NV; Filatov AV
Glycobiology; 2012 Apr; 22(4):529-42. PubMed ID: 22143985
[TBL] [Abstract][Full Text] [Related]
11. Specificity of human natural antibodies referred to as anti-Tn.
Dobrochaeva K; Khasbiullina N; Shilova N; Antipova N; Obukhova P; Ovchinnikova T; Galanina O; Blixt O; Kunz H; Filatov A; Knirel Y; LePendu J; Khaidukov S; Bovin N
Mol Immunol; 2020 Apr; 120():74-82. PubMed ID: 32087569
[TBL] [Abstract][Full Text] [Related]
12. Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors.
Balakrishnan A; Rajan A; Salter AI; Kosasih PL; Wu Q; Voutsinas J; Jensen MC; Plückthun A; Riddell SR
Clin Cancer Res; 2019 Dec; 25(24):7506-7516. PubMed ID: 31548346
[TBL] [Abstract][Full Text] [Related]
13. Antibody recognition of a unique tumor-specific glycopeptide antigen.
Brooks CL; Schietinger A; Borisova SN; Kufer P; Okon M; Hirama T; Mackenzie CR; Wang LX; Schreiber H; Evans SV
Proc Natl Acad Sci U S A; 2010 Jun; 107(22):10056-61. PubMed ID: 20479270
[TBL] [Abstract][Full Text] [Related]
14. Diverse glycosylation of MUC1 and MUC2: potential significance in tumor immunity.
Irimura T; Denda K; Iida Si; Takeuchi H; Kato K
J Biochem; 1999 Dec; 126(6):975-85. PubMed ID: 10578046
[TBL] [Abstract][Full Text] [Related]
15. Molecular basis of incomplete O-glycan synthesis in MCF-7 breast cancer cells: putative role of MUC6 in Tn antigen expression.
Freire T; Bay S; von Mensdorff-Pouilly S; Osinaga E
Cancer Res; 2005 Sep; 65(17):7880-7. PubMed ID: 16140958
[TBL] [Abstract][Full Text] [Related]
16. Serine versus threonine glycosylation with α-O-GalNAc: unexpected selectivity in their molecular recognition with lectins.
Madariaga D; Martínez-Sáez N; Somovilla VJ; García-García L; Berbis MÁ; Valero-Gónzalez J; Martín-Santamaría S; Hurtado-Guerrero R; Asensio JL; Jiménez-Barbero J; Avenoza A; Busto JH; Corzana F; Peregrina JM
Chemistry; 2014 Sep; 20(39):12616-27. PubMed ID: 25111627
[TBL] [Abstract][Full Text] [Related]
17. Identification of a secondary binding site in human macrophage galactose-type lectin by microarray studies: Implications for the molecular recognition of its ligands.
Marcelo F; Supekar N; Corzana F; van der Horst JC; Vuist IM; Live D; Boons GPH; Smith DF; van Vliet SJ
J Biol Chem; 2019 Jan; 294(4):1300-1311. PubMed ID: 30504228
[TBL] [Abstract][Full Text] [Related]
18. Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells.
Gao Z; Tong C; Wang Y; Chen D; Wu Z; Han W
J Genet Genomics; 2019 Aug; 46(8):367-377. PubMed ID: 31466926
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibodies toward different Tn-amino acid backbones display distinct recognition patterns on human cancer cells. Implications for effective immuno-targeting of cancer.
Mazal D; Lo-Man R; Bay S; Pritsch O; Dériaud E; Ganneau C; Medeiros A; Ubillos L; Obal G; Berois N; Bollati-Fogolin M; Leclerc C; Osinaga E
Cancer Immunol Immunother; 2013 Jun; 62(6):1107-22. PubMed ID: 23604173
[TBL] [Abstract][Full Text] [Related]
20. Chimeric Antigen Receptors Based on Low Affinity Mutants of FcεRI Re-direct T Cell Specificity to Cells Expressing Membrane IgE.
Ward DE; Fay BL; Adejuwon A; Han H; Ma Z
Front Immunol; 2018; 9():2231. PubMed ID: 30364107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
